fda decision tirzepatide Grants a New Indication for Obesity Management FDA approves new version of

Activated charcoal

Tirzepatide is a dual agonist acting on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

The slower emptying of the stomach sends a signal of fullness to the brain

Common Side Effects Mild nausea (most common, usually improves within a few weeks) Diarrhea or constipation due to slowed digestion Bloating or fullness after meals Mild headaches or fatigue Less Common But Serious Side Effects Pancreatitis (rare) Watch for persistent, severe abdominal pain. Hypoglycemia (rare in non-diabetics) Can occur when combined with insulin therapy. Allergic reactions (very rare) Monitor for rash, swelling, or difficulty breathing

See Instructions for Use for more information